ANDA 214615, held by Apotex. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 214615 (Triamcinolone Acetonide), held by Apotex, was first approved by FDA on Jan 19, 2023, with 0 approved supplements and 0 published complete response letters.
Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion runny nose sneezing itchy nose
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 19, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.055MG/SPRAY · spray, metered;nasal | Triamcinolone Acetonide | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
